Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of Daptomycin in Japanese Pediatric Patients With Complicated Skin and Soft Tissue Infections or Bacteremia
2020-001576-15Phase 2
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daptomycin in skin and soft tissue infections (SSTIs), Bacteremia and Staphylococcus aureus infection, sponsored by Merck & Co. Primary endpoint: Percentage of participants with an Adverse Event.
02
Drugs
daptomycin
03
Conditions
skin and soft tissue infections (SSTIs)BacteremiaStaphylococcus aureus infection
Beyond the preview
Go deeper on 2020-001576-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001576-15.